Pasithea Therapeutics Corp (KTTA)

$1.13 +0.01 (0.89%)
Market Cap 8.41M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 366,700
Avg Vol 8,699,331
Day's Range N/A - N/A
Shares Out 7.44M
Stochastic %K 33%
Beta 0.21
Analysts Sell
Price Target $3.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
PrimedJewel
PrimedJewel Dec. 14 at 5:07 AM
$KTTA good time to add.
0 · Reply
TheMFBearKillla
TheMFBearKillla Dec. 11 at 1:48 PM
$KTTA bullish explosion building! Momentum is here! 🚀
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 9 at 12:19 AM
$INHD 🚀 $PAVS $KTTA
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:38 PM
HC Wainwright & Co. updates rating for Pasithea Therapeutics ( $KTTA ) to Buy, target set at 3.
0 · Reply
BruceFree07
BruceFree07 Dec. 8 at 12:30 PM
$KTTA
0 · Reply
SpartanTrader117
SpartanTrader117 Dec. 5 at 2:00 PM
$KTTA $SMX $YDKG $YDKG is next
0 · Reply
Alessandro437
Alessandro437 Dec. 5 at 1:10 PM
$SMX this is awesome 🚀🚀🚀 Who is is next $KTTA OR $YDKG ☢️🚀
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 4 at 9:53 PM
$KTTA ww
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 4 at 5:48 PM
$INHD $KTTA Christmas coming early ! $SMX on the move! $125?! $BGL $UPC 👀 next
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 4 at 2:41 PM
$KTTA Set up
0 · Reply
Latest News on KTTA
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Dec 2, 2025, 7:00 AM EST - 12 days ago

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Nov 28, 2025, 9:20 AM EST - 15 days ago

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Nov 24, 2025, 7:00 AM EST - 20 days ago

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Nov 21, 2025, 12:35 PM EST - 22 days ago

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Nov 20, 2025, 4:01 PM EST - 23 days ago

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Nov 4, 2025, 7:03 AM EST - 5 weeks ago

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Sep 16, 2025, 7:03 AM EDT - 3 months ago

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:39 AM EDT - 3 months ago

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 4 months ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 6 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 6 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 7 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 7 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 7 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 7 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:29 AM EDT - 7 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 7 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 8 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 8 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 8 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 11 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 11 months ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 1 year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 1 year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 30, 2023, 9:28 AM EDT - 2 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Jun 1, 2023, 7:57 AM EDT - 2 years ago

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

May 3, 2023, 8:26 AM EDT - 2 years ago

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Feb 23, 2023, 8:00 AM EST - 3 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

PrimedJewel
PrimedJewel Dec. 14 at 5:07 AM
$KTTA good time to add.
0 · Reply
TheMFBearKillla
TheMFBearKillla Dec. 11 at 1:48 PM
$KTTA bullish explosion building! Momentum is here! 🚀
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 9 at 12:19 AM
$INHD 🚀 $PAVS $KTTA
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 2:38 PM
HC Wainwright & Co. updates rating for Pasithea Therapeutics ( $KTTA ) to Buy, target set at 3.
0 · Reply
BruceFree07
BruceFree07 Dec. 8 at 12:30 PM
$KTTA
0 · Reply
SpartanTrader117
SpartanTrader117 Dec. 5 at 2:00 PM
$KTTA $SMX $YDKG $YDKG is next
0 · Reply
Alessandro437
Alessandro437 Dec. 5 at 1:10 PM
$SMX this is awesome 🚀🚀🚀 Who is is next $KTTA OR $YDKG ☢️🚀
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 4 at 9:53 PM
$KTTA ww
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Dec. 4 at 5:48 PM
$INHD $KTTA Christmas coming early ! $SMX on the move! $125?! $BGL $UPC 👀 next
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 4 at 2:41 PM
$KTTA Set up
0 · Reply
dbr_island
dbr_island Dec. 3 at 11:42 PM
$PLRZ if you missed this $EPOW is my next one 🚨🚨🚨🚨🚨🚨 And I want $5+ at MINIMUM I also called $CAPR $SMX $KTTA all LIFE CHANGERS 🏆✅
0 · Reply
A1DAYTRADER
A1DAYTRADER Dec. 3 at 9:23 PM
$KTTA 300%🚀👀💵💵 CATCH MY ALERTS EARLY BEFORE THE RUN UP!!💵🚀👀💵 $QCLS $CAPR $VRAX $PAVS
0 · Reply
dbr_island
dbr_island Dec. 3 at 5:01 PM
$KTTA watching 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
damnbruh
damnbruh Dec. 3 at 3:59 PM
$KTTA
0 · Reply
dbr_island
dbr_island Dec. 3 at 3:02 PM
$KTTA watching 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
Adrrin11
Adrrin11 Dec. 3 at 2:56 PM
$KTTA
0 · Reply
Dietlinde38
Dietlinde38 Dec. 3 at 2:52 PM
$KTTA
0 · Reply
_Sonic_Scalps
_Sonic_Scalps Dec. 3 at 1:56 PM
Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $BOX $AEVA $KTTA $BB Like them
0 · Reply
dbr_island
dbr_island Dec. 3 at 1:29 PM
$KTTA watching closely… 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
JL_TradeZ
JL_TradeZ Dec. 3 at 2:29 AM
Main Watchlist – Wed 12/03 $PMAX had a strong day with almost 10M volume on a small float. If it holds 3.20 tomorrow, it has room for another leg $BQ saw a big shift in momentum today with volume exploding and the chart holding quite well into the close. Watching 2.80 for a breakout $KTTA held its pullback nicely and steady volume. Small float and setting up a higher low. Watching for a move over 1.30 $CMCT still has some momentum left after the Echo Park news. Float's under 1M and steady volume. Could push again if it holds trend. $VSME bounced off with volume almost 4x the average and reclaimed the short-term trend. Watching 0.17-0.18 for a breakout
0 · Reply
DaBullRunner
DaBullRunner Dec. 2 at 11:43 PM
$SERV you ignored me here in the $4’s Now it’s $10 🚨EPOW🚨just received a $30M contract AH This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into TOVX👇💰💰💰 $SMX $PLRZ $FOXX $KTTA let’s get it
0 · Reply
SpartanVI
SpartanVI Dec. 2 at 11:05 PM
$LGVN $PRZO $KTTA $FLYE $SMX ⏰️🔥
0 · Reply